Lexeo Therapeutics, Inc. (LXEO)
NASDAQ: LXEO · Real-Time Price · USD
4.550
-0.140 (-2.99%)
At close: Jul 20, 2026, 4:00 PM EDT
4.550
0.00 (0.00%)
After-hours: Jul 20, 2026, 4:10 PM EDT

Lexeo Therapeutics Stock Forecast

Stock Price Forecast

According to 10 analysts polled by S&P Global, Lexeo Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $20.89. The average 1-year stock price forecast is 359.12% higher than the current stock price, while the lowest is $9.00 (+97.80%) and the highest is $30 (+559.34%).

Price Target: $20.89 (+359.12%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$9.00$20.89$20$30
Change+97.80%+359.12%+339.56%+559.34%

Analyst Ratings

The average analyst rating for Lexeo Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingFeb '26Mar '26Apr '26May '26Jun '26Jul '26
Strong Buy999888
Buy222222
Hold000000
Sell000000
Strong Sell000000
Total111111101010

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Stifel Nicolaus
Stifel Nicolaus
Buy
Maintains
$17
BuyMaintains$17+273.63%Jul 6, 2026
J.P. Morgan
J.P. Morgan
Buy
Maintains
$12$9
BuyMaintains$12$9+97.80%Jun 25, 2026
RBC Capital
RBC Capital
Buy
Maintains
$20
BuyMaintains$20+339.56%May 12, 2026
Chardan Capital
Chardan Capital
Buy
Reiterates
$17
BuyReiterates$17+273.63%May 11, 2026
Oppenheimer
Oppenheimer
Buy
Reiterates
$20
BuyReiterates$20+339.56%Mar 31, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
6.11M
EPS This Year
-1.14
from -1.93
EPS Next Year
-1.24
from -1.14
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
1.66M654.00K----
Operating Income
-50.64M-60.51M-68.51M-105.77M-109.26M-105.11M
Net Income
-50.62M-59.28M-66.39M-98.33M-99.96M-97.88M
EPS
-----1.93-1.14
Free Cash Flow
-25.48M-33.67M-35.22M-48.43M-62.60M-100.50M
No. Analysts
-----10
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
Highn/a
Avgn/a
Lown/a

Revenue Growth

Revenue Growth20272028
High-
Avg-
Low-

EPS Forecast

EPS202620272028
High-0.99
Avg-1.14
Low-1.28

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-